A Study to Evaluate Safety, Tolerability and Preliminary Activity of AGX101 in Participants With Advanced Solid Tumors

Launched by ANGIEX, INC. · May 30, 2024

Keywords

ClinConnect Summary

This clinical trial is studying a new treatment called AGX101, which is an antibody-drug conjugate designed for patients with advanced solid tumors, including types of cancer like triple-negative breast cancer and pancreatic cancer. The main goal of the study is to assess how safe AGX101 is and how well it works at different dose levels. Participants will receive AGX101 through an intravenous (IV) infusion every three weeks. The treatment may continue until the cancer worsens, side effects become too severe, or a participant decides to stop.

To be eligible for this trial, patients must have certain types of advanced cancers that cannot be surgically removed and must have already tried standard treatments without success. Key criteria include being in generally good health with proper organ function and not having specific types of cancer or other serious health conditions that would complicate treatment. Participants will have regular follow-ups, including safety checks after treatment ends. This trial is currently looking for participants of all genders, aged 65 to 74 and older.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • Histologically confirmed unresectable, locally advanced, or metastatic solid tumors.
• • Refractory to or relapsed after all standard therapies known to provide proven clinical benefit, unless the patient is not a candidate for standard treatment, there is no standard treatment, or the patient refuses standard treatment after expressing an understanding of all available therapies with proven clinical benefit
• • Willing to authorize use of existing archival tissue, unless otherwise discussed with Sponsor
• • Time since the last dose of prior therapy to treat underlying malignancy (including other investigational therapy): Systemic cytotoxic chemotherapy: ≥ the duration of the most recent cycle of the previous regimen (with a minimum of 2 weeks for all, except 6 weeks for systemic nitrosourea or systemic mitomycin-C); Biologic therapy (eg, antibodies): ≥ 3 weeks; Small molecule therapies: ≥ 5 × half-life
• • Have an ECOG performance status of 0 to 1
• • Have adequate organ function
• • LVEF ≥ 50%, as determined on cardiac ECHO or cardiac multiple-gated acquisition (MUGA) scan
• • Highly effective contraception for both male and female patients throughout the study
• Exclusion Criteria:
• • Colorectal cancer patients with an unresected primary colorectal tumor and non-small-cell lung cancer with predominant squamous histology (ie, squamous cell carcinoma of the lung) are excluded unless otherwise discussed and approved by Sponsor
• • Clinically unstable central nervous system (CNS) tumors or brain metastasis (stable and/or asymptomatic CNS metastases allowed)
• • Have not recovered to ≤ Grade 1 or baseline from all AEs due to previous therapies (patients with ≤ Grade 2 neuropathy, endocrine-related irAEs, or other AEs may be eligible after discussion with the Sponsor)
• • Has an active vasculitis that has required systemic treatment in the past 2 years prior to starting study treatment
• • Significant (ie, ≥ Grade 2) ocular disturbances
• • Variceal bleeding within 6 months prior to treatment, currently untreated or incompletely treated varices with bleeding, or who otherwise are at a high risk of bleeding
• • Any other concurrent antineoplastic treatment except for allowed local radiation of lesions for palliation (to be considered non-target lesions after treatment) and hormone ablation
• • Uncontrolled or life-threatening symptomatic concomitant disease, including known symptomatic HIV positive with an AIDS defining opportunistic infection within the last year, known symptomatic active hepatitis B or C, or known active tuberculosis
• • Has undergone a major surgery within 3 weeks prior to starting study treatment or has inadequate healing or recovery from complications of surgery prior to starting study treatment
• • Has received prior radiotherapy within 2 weeks prior to starting study treatment
• • Has or had a potentially life-threatening second malignancy requiring systemic treatment within the last 3 years, or which would impede evaluation of treatment response
• • Clinically significant cardiovascular disease
• • Patients on a potent CYP3A inhibitor or CPY3A inducer who cannot be changed to another medication
• • Has an active infection requiring concurrent systemic antibiotic therapy
• • A woman of child-bearing potential (WOCBP) who has a positive pregnancy test prior to treatment
• • Is breastfeeding or expecting to conceive or father children within the projected duration of the study